Discovery puts the brakes on HIV's ability to infect

November 30, 2017

Viewed with a microscope, the virus faintly resembles a pineapple--the universal symbol of welcome. But HIV, the virus that causes AIDS, is anything but that. It has claimed the lives of more than 35 million people so far.

In a study led by the University of Delaware and the University of Pittsburgh School of Medicine, researchers discovered a "brake" that interferes with HIV's development into an infectious agent. This mechanism prevents the capsid--the protein shell covering the virus -- from forming.

The finding, which was published in Nature Communications, was made by an interdisciplinary research team from UD, the University of Pittsburgh School of Medicine, University of Illinois, National Cancer Institute, DFH Pharma and Vanderbilt University Medical Center. The results are based on seven years of excruciatingly detailed studies of the structure and dynamics of HIV early and late in its life cycle. The movements of the virus molecules were measured experimentally and simulated in quadrillionths of a second--that's much faster than the blink of an eye or the flutter of a hummingbird's wings.

"People used to be fixated on the static structures of viruses, but they are not rock solid," said Tatyana Polenova, professor in UD's Department of Chemistry and Biochemistry. She is an expert in nuclear magnetic resonance (NMR) spectroscopy, which helps scientists identify and pinpoint the location of every atom in a structure and how each atom moves.

"Viruses like HIV and their constituent protein and nucleic acid molecules are dynamic entities that are constantly expanding and shrinking," she added. "Their motions are like breathing."

Polenova said molecules in the HIV virus operate in concert, yet within each molecule motions occur over many different time scales, a difficult scenario to simulate, to be sure. But not too complex for Juan Perilla, who joined the UD faculty as an assistant professor this past June. A quantitative biophysicist, Perilla created the first structural models of HIV as a postdoctoral scientist at the University of Illinois. Today, at UD, he routinely uses some of the world's largest supercomputers to generate simulations of the HIV virus and its many moving parts.

Stopping a virus from maturing

As the HIV virus develops, a cascade of events occurs, affecting its structure and ability to infect. Think of the TV cooking show "Chopped." But in this case, protein building blocks get methodically "cleaved" or cut from a larger, master protein called Gag.

By integrating state-of-the-art techniques, including solid-state and solution NMR, high-end computer simulations, and cryo-electron microscopy (for which the Nobel Prize was awarded earlier this fall) the researchers answered a longstanding question about how the final step in the maturation of the virus occurs--a process in which a noninfectious immature virion turns into an infectious virus particle.

The team discovered that a key peptide--spacer peptide 1 (SP1)--has to be in a highly mobile structure to be cut by the virus protease, the enzyme that acts like a cleaver. In simulations, the peptide resembles a thin, yarn-like strand attached to corkscrews of curled ribbons in constant motion.

"This peptide is always there in the final maturation step, but we were surprised that it is so disordered and dynamic," Polenova said.

Once the SP1 peptide is cut, the HIV virus forms its protective capsid and becomes infectious. But how do you stop that process? In team experiments at the University of Pittsburgh led by Angela Gronenborn, the anti-HIV inhibitor Bevirimat was shown to interact with the SPI peptide, thus preventing the development of the virus's capsid "coat."

Zeroing in on potential drug targets to stop HIV from becoming infectious by disrupting the virus's maturation is an ongoing goal for the team.

"We have to have a sense of these short-lived molecular fluctuations and processes--of protein cleavage and capsid generation," Perilla said. "To add a new generation of capsid inhibitors to prevent HIV, you have to have very specific times and rates at which these drugs will work."

Perilla and Polenova also said an extensive team of people is critical, including experimentalists and computational scientists, who have expertise in multiple biophysical techniques, such as NMR and cryo-EM, and across the disciplines of structural biology, biophysics, biochemistry and virology.

"This work would be impossible without our combined strength--I tell my students they need to learn to collaborate with people in other fields," said Polenova. Also critical, she said, is the availability of cutting edge infrastructure in high-field NMR at the University of Delaware and at ultra-high field NMR centers across the U.S., including the National High Magnetic Field Laboratory, and internationally, such as the National Center for Scientific Research in Lyon, France, where Polenova and her students travel to perform NMR experiments.

She and Perilla both credit Angela Gronenborn, their collaborator at the University of Pittsburgh, for transforming their work through the Pittsburgh Center for HIV Protein Interactions, a national research center that Gronenborn established about a decade ago with funding from the National Institutes of Health.

"Science is moving away from the single scientist being able to peer at things at atomic resolution," Polenova said. "It's no longer the situation of doing one thing as a single investigator. Now, we all come together."

The research was funded by the National Institutes of Health.
-end-
In addition to Polenova and Perilla, other UD authors of the paper included doctoral student Mingzhang "Maple" Wang, staff scientists Caitlin Quinn and Guangjin Hou, and postdoctoral researchers Huilan Zhang and Christopher Suiter--all from the UD Department of Chemistry and Biochemistry. Authors from the University of Pittsburgh School of Medicine included Angela Gronenborn, Randall Shirra, Jr., In-Ja Byeon and Peijun Zhang. Eric O. Freed from the National Cancer Institute, Theodore J. Nitz from DFH Pharma, and Klaus Schulten from the University of Illinois also were co-authors.

University of Delaware

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.